Polyphor par­lays a pathogen-spe­cif­ic an­tibi­ot­ic and I/O work in­to a $165M IPO for its PhI­II pro­gram

Polyphor has suc­cess­ful­ly com­plet­ed an IPO, rais­ing about $165 mil­lion to back its Phase III de­vel­op­ment of a new an­tibi­ot­ic specif­i­cal­ly de­signed to coun­ter­at­tack against Pseudomonas aerug­i­nosa along with an easy-stage shot at im­muno-on­col­o­gy.

The biotech priced an up­sized lot of shares at 38 Swiss Francs — or about $38 — for the of­fer­ing on the Swiss bourse. That makes for a fair­ly un­usu­al hit, with many Eu­ro­pean biotechs drawn to try their luck on the free­wheel­ing Nas­daq, where ear­ly-stage, high-risk biotechs have pulled off a string of suc­cess­ful rais­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.